Navigation Links
Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
Date:10/6/2009

stated strategy of conducting a well-controlled, Phase III confirmatory clinical trial in addition to its planned U.S. Phase II/III trial in order to establish the efficacy and safety of its product for marketing authorization purposes. Helix intends to continue to make preparations to conduct a European Phase III trial for this purpose. The timing of filing the regulatory submissions for this trial has not yet been established, however, it is not expected to precede the filing of its planned U.S. Phase II/III IND.

Topical Interferon Alpha-2b - Anogenital Warts Indication

Enrollment in the ongoing Phase II clinical trial of Topical Interferon Alpha-2b in patients with anogenital warts ("AGW") in Sweden and Germany is progressing on track. The Company expects the last patient to be enrolled on or around the end of the first quarter of fiscal 2010. The study has now enrolled over 85% of the required 120 patients. Future considerations for the AGW program were not part of the latest pre-IND meetings, as Helix is awaiting the results from the ongoing Phase II AGW trial prior to initiating further development plans for this indication.

L-DOS47

At the pre-IND meeting with the FDA for L-DOS47, the FDA generally agreed with Helix's proposed remaining non-clinical pharmacology and toxicology studies as well as its remaining GMP manufacturing program initiatives prior to IND filing. The FDA provided Helix with recommendations for improvements in some areas including the development of additional quality control analytical testing methods to characterize batches of L-DOS47 clinical supplies and their intermediates.

As previously stated, Helix intends to initiate its clinical testing program with L-DOS47 with studies in both North America and in Europe. In Europe, Helix has been developing relationships with key opinion leader clinicians and contract research organizations in Poland with a plan to co
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
2. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
3. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
4. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
5. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
6. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
7. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
11. Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 Trovagene, Inc. (NASDAQ:   TROV), ... results from two clinical studies will be presented at ... urine-based diagnostic test for the detection of high risk ... scheduled to take place in Seattle ... . Additionally, a new U.S. patent was issued earlier ...
(Date:8/20/2014)... Reportlinker.com announces that ... its catalogue: EMR 2014: The Market ... http://www.reportlinker.com/p0833392/EMR-2014-The-Market-for-Electronic-Medical-Records.html Kalorama has continuously examined ... for nearly a decade, and each year we ... report has become the industry standard, oft-quoted by ...
(Date:8/20/2014)... Glenmark Pharmaceuticals S.A. (GPSA), ... India (GPL), announces the discovery and initiation of ... candidate, GBR 1302, a HER2xCD3 bispecific antibody. GBR ... Biologics Research Centre located in La Chaux-de-Fonds, ... on Glenmark,s innovative BEAT antibody technology platform which ...
Breaking Medicine Technology:Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3EMR 2014: The Market for Electronic Medical Records 2EMR 2014: The Market for Electronic Medical Records 3EMR 2014: The Market for Electronic Medical Records 4EMR 2014: The Market for Electronic Medical Records 5EMR 2014: The Market for Electronic Medical Records 6EMR 2014: The Market for Electronic Medical Records 7EMR 2014: The Market for Electronic Medical Records 8Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3
(Date:8/20/2014)... August 20, 2014 The Workgroup ... nonprofit authority on the use of health IT ... the full agenda for its annual fall conference, ... Efficiency. WEDI-Con 2014 will take place at the ... 2014, attracting a diverse cross-section of payers, providers, ...
(Date:8/20/2014)... Doctors at the University of Hong Kong claim to ... mice by injecting them with a vaccine that changes their ... on its website. Click here to read the full ... Institute of Microbiology created a vaccine using a protein called ... the vaccine is designed to prevent mesothelioma cells from disabling ...
(Date:8/20/2014)... August 20, 2014 Today, Zane Benefits, ... on open enrollment for 2015. , According to Zane ... up in November, employees are encouraged to start thinking ... in 2015, the open enrollment period will run from ... enrollment 2015 individuals can purchase a new individual health ...
(Date:8/20/2014)... The report “Automotive Airbag and ... Global Analysis: by Geography - Trends and Forecasts ... defines automotive airbag and seatbelt market in terms ... growth opportunities in the coming years as well ... restrains, growth indicators, challenges, legislation trends, market dynamics, ...
(Date:8/20/2014)... In a recent article published by ... London (UCL) study showed that dental experts from around ... teeth was the most effective. Analysis of 66 different ... were frequently recommended, but none were favored by a ... experienced cosmetic dentist Dr. Patrick J. Broome, ...
Breaking Medicine News(10 mins):Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 3Health News:New Research Study Finds Vaccine Stops Mesothelioma in Lab Mice, According to Surviving Mesothelioma Website 2Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 4Health News:Ending Confusion About the Best Way to Brush Teeth 2Health News:Ending Confusion About the Best Way to Brush Teeth 3
... ... Interim Leadership division as senior vice president. A seasoned executive with nearly 20 years of ... , ... 2009 -- B. E. Smith recently hired Deirdre Byrne to lead the firm’s ...
... , MIAMI, Dec. 17 Physicians Healthcare ... today announced that it has issued its financial statements for ... being posted today on the Pink Sheets (www.pinksheets.com). ... , Physicians Healthcare Management Group, Inc. (Phyhealth) is a developer ...
... the employment and sociodemographic characteristics involved in the exposure of ... often work standing up or have to lift heavy objects, ... are frequently exposed to some physical risk in their place ... to exposure to workplace hazards", M Carmen Gonzlez, lead author ...
... PITTSBURGH, Dec. 17 Stem cells that could one day ... easily harvested from the tissue of the umbilical cord, just ... to treat some blood disorders, said University of Pittsburgh School ... the Journal of Biomedicine and Biotechnology . ...
... ... Online , ... Fla. (PRWEB) December 17, 2009 -- Open enrollment has begun for Villanova’s newly online ... schedules can’t accommodate a campus-based program. With the university’s Master of Science in Human ...
... 17 CareFusion Corporation (NYSE: CFN ) announced today ... TRC Capital Corporation (TRC) to purchase up to four million shares ... of common stock outstanding. TRC,s offer price of $23.50 per share ... stock on Dec. 14, 2009, the last full trading day prior ...
Cached Medicine News:Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 2Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 3Health News:Phyhealth Issues September 30, 2009 Financial Statements 2Health News:Almost two-thirds of pregnant women believe they are regularly exposed to physical risk at work 2Health News:Umbilical cord could be new source of plentiful stem cells, say Pitt researchers 2Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 2Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 3Health News:CareFusion Recommends Rejection of Mini-Tender Offer by TRC Capital 2
The NOW Flu A test is the most frequently adopted rapid flu test on the market today. Testing could not be easier and the results are available in 15 minutes. Now you can focus on the results and tre...
... The Shandon Finesse ME+ is designed ... in todays busy laboratories by being one ... microtomes offered today. Excellent for routine wax ... Finesse ME + provides high quality sections ...
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
The Shandon Linistat Linear Stainer is a compact answer to H&E frozen section protocols, with a footprint that fits on top of most cryostas to streamline workflow during frozen sectioning....
Medicine Products: